Abstract

BackgroundAdvanced age-related macular degeneration (AMD) is a leading cause of blindness. While around half of the genetic contribution to advanced AMD has been uncovered, little is known about the genetic architecture of early AMD.MethodsTo identify genetic factors for early AMD, we conducted a genome-wide association study (GWAS) meta-analysis (14,034 cases, 91,214 controls, 11 sources of data including the International AMD Genomics Consortium, IAMDGC, and UK Biobank, UKBB). We ascertained early AMD via color fundus photographs by manual grading for 10 sources and via an automated machine learning approach for > 170,000 photographs from UKBB. We searched for early AMD loci via GWAS and via a candidate approach based on 14 previously suggested early AMD variants.ResultsAltogether, we identified 10 independent loci with statistical significance for early AMD: (i) 8 from our GWAS with genome-wide significance (P < 5 × 10− 8), (ii) one previously suggested locus with experiment-wise significance (P < 0.05/14) in our non-overlapping data and with genome-wide significance when combining the reported and our non-overlapping data (together 17,539 cases, 105,395 controls), and (iii) one further previously suggested locus with experiment-wise significance in our non-overlapping data. Of these 10 identified loci, 8 were novel and 2 known for early AMD. Most of the 10 loci overlapped with known advanced AMD loci (near ARMS2/HTRA1, CFH, C2, C3, CETP, TNFRSF10A, VEGFA, APOE), except two that have not yet been identified with statistical significance for any AMD. Among the 17 genes within these two loci, in-silico functional annotation suggested CD46 and TYR as the most likely responsible genes. Presence or absence of an early AMD effect distinguished the known pathways of advanced AMD genetics (complement/lipid pathways versus extracellular matrix metabolism).ConclusionsOur GWAS on early AMD identified novel loci, highlighted shared and distinct genetics between early and advanced AMD and provides insights into AMD etiology. Our data provide a resource comparable in size to the existing IAMDGC data on advanced AMD genetics enabling a joint view. The biological relevance of this joint view is underscored by the ability of early AMD effects to differentiate the major pathways for advanced AMD.

Highlights

  • Advanced age-related macular degeneration (AMD) is a leading cause of blindness

  • Interaction analyses For the novel early Age-related macular degeneration (AMD) effects and for the 34 known advanced AMD lead variants [9], we investigated whether age modulated early AMD effects by analyzing variant x age interaction in seven data sources for which we had individual participant data available in Regensburg (ARIC, Cardiovascular Health Study (CHS), Women's Health Initiative (WHI), International AMD genomics consortium (IAMDGC), UK biobank (UKBB), Age-related diseases (AugUR) and KOoperative Gesundheitsforschung in der Region Augsburg (KORA))

  • Based on logistic regression association analysis in each of the 11 data sets meta-analyzed via fixed effect model, we identified eight distinct loci with genome-wide significance

Read more

Summary

Introduction

Advanced age-related macular degeneration (AMD) is a leading cause of blindness. Age-related macular degeneration (AMD) is the leading cause of irreversible central vision impairment in industrialized countries. Advanced AMD is preceded by clinically asymptomatic and often unrecognized early disease stages. Other features of early AMD are RPE abnormalities, including depigmentation or increased amount of pigment [1]. And advanced AMD can be documented by color fundus imaging of the central retina and/or other multimodal imaging approaches including optical coherence tomography (OCT) [1,2,3]. While the definition of advanced AMD is reasonably homogeneous across clinical and epidemiological studies, the classification of early AMD is more variable and different studies traditionally apply differing classification systems [4, 5]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call